Evidence map›Paper›PMID 32934718›Full record

ArticleOncology letters2020

Comparative effectiveness of surgery and radiotherapy for survival of patients with clinically localized prostate cancer: A population-based coarsened exact matching retrospective cohort study.

Masato Yasui, Masahiko Sakaguchi, Ryousuke Jikuya, Sohgo Tsutsumi, Tomoyuki Tatenuma, Go Noguchi, Susumu Umemoto, Kayako Katayama, Hiroto Narimatsu, Hiroji Uemura and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Comparative analysis of treatment decision-making in patients with localized prostate and cervical cancer: what influences receiving surgery or radiotherapy?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Masato YasuiDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Masahiko SakaguchiKanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241-8515, Japan.
Ryousuke JikuyaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Sohgo TsutsumiDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Tomoyuki TatenumaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Go NoguchiDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Susumu UmemotoDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Kayako KatayamaKanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241-8515, Japan.
Hiroto NarimatsuKanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241-8515, Japan.
Hiroji UemuraDepartment of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Kanagawa 232-0024, Japan.
Takeshi KishidaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Kanagawa Cancer CenterKanagawa Prefectural Hospital Organization · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radical prostatectomy and radiotherapy are currently the main treatment options for localized prostate cancer. However, no large cohort study comparing surgery and radiation has been performed in Japan or Asia. The objective of the current study was to compare the survival outcomes of patients with clinically localized prostate cancer and in elderly and young patients receiving surgery and radiotherapy. The survival outcomes of patients with localized prostate cancer (age at diagnosis ≤79 years, clinical T1-3) initially treated with surgery or radiotherapy were retrospectively analyzed. Data were collected from the population-based cancer registry of the Kanagawa Prefecture, Japan. A 1:1 coarsened exact matching of age at diagnosis, clinical T stage and cancer differentiation was performed between the two treatment groups. Patients were also categorized into two subgroups by age using a cutoff of 70 years for analysis. The cohort comprised 4,810 patients aged 50-79 years. No significant difference in cancer-specific survival (CSS) was observed between the two groups (P=0.612). However, the surgery group had significantly better overall survival (OS; P=0.004). When stratified for age, similar tendencies were observed in the elderly group (aged 70-79 years; CSS, P=0.961 and OS, P=0.007). No significant difference in either CSS or OS was identified in the younger group (P=0.550 and P=0.408, respectively). Intrinsic deaths were more likely to occur in elderly patients treated with radiotherapy than those undergoing surgery (69.3 vs. 78.2%; P=0.128). The results indicated that surgery provided significantly better OS than radiotherapy, particularly among the elderly. However, no significant difference was observed in CSS. These results should be interpreted with caution, given that some important factors were unavailable in the present study, such as prostate-specific antigen values and Gleason scores. Prospective trials evaluating these therapies are warranted.

Indexed as

cancer-specific survivalexact matchingoverall survivalprostate cancerradiotherapysurgery

Identifiers

PMID32934718
PMCPMC7475640
OpenAlexW3080921966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.